Evidence map›Paper›PMID 37981582›Full record

ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2023

Gadolinium(III) complex formation with a β-cyclodextrin ligand: an XAS study of a potential MRI contrast agent.

Farideh Jalilehvand, Saba Homayonia, Ping Zhang, Chang-Chun Ling

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Farideh JalilehvandDepartment of Chemistry, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada. faridehj@ucalgary.ca.ORCID 0000-0002-6298-8187
Saba HomayoniaDepartment of Chemistry, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada.
Ping ZhangDepartment of Chemistry, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada.
Chang-Chun LingDepartment of Chemistry, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada. ccling@ucalgary.ca.ORCID 0000-0003-0802-7729

Funding

Canada Foundation for Innovation 16669Canada Foundation for Innovation 9479Natural Sciences and Engineering Research Council of Canada RGPIN 2016-04546Natural Sciences and Engineering Research Council of Canada RGPIN 2018-04320Natural Sciences and Engineering Research Council of Canada RGPIN 2022-02996The Canadian Lightsource Proposal 31G10937
6 · The paper itself

Abstract

In the search for improved and safer gadolinium-based magnetic resonance imaging (MRI) contrast agents, macrocyclic cyclodextrins (CDs) attract great interest. Our group previously synthesized a cyclodextrin-based ligand with 1,2,3-triazolmethyl residues conjugated to β-CD, called β-CD(A), which efficiently chelates Gd(III) ions. To probe the local structure around the Gd(III) ion in the 1:1 Gd(III): β-CD(A) complex in aqueous solution (pH 5.5), we used extended X-ray absorption fine structure (EXAFS) spectroscopy. Least-squares curve fitting of the Gd L

Indexed as

beta-CyclodextrinsCyclodextrinsContrast MediaGadoliniumHeterocyclic CompoundsLigandsMagnetic Resonance ImagingOrganometallic Compoundsbeta-CyclodextrinsContrast MediaCyclodextrinsGadoliniumgadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetateHeterocyclic CompoundsLigandsOrganometallic CompoundsEXAFSGadoliniumMRI contrast agentStructureβ-Cyclodextrin

Identifiers

PMID37981582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.